Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.8.0.1
Commitments and Contingencies (Details Textual)
 1 Months Ended 9 Months Ended
Jul. 09, 2015
USD ($)
Sep. 12, 2013
USD ($)
Feb. 21, 2017
USD ($)
Jun. 17, 2016
USD ($)
Feb. 15, 1999
USD ($)
Sep. 30, 2017
USD ($)
ft²
Jul. 06, 2016
ft²
Commitments and Contingencies [Line Items]              
Area of Land | ft²             2,300
License Expiration Period         12 years    
License Costs   $ 50,000   $ 15,000 $ 12,500    
Proceeds From Upfront Payment     $ 4,000,000        
Minimum [Member]              
Commitments and Contingencies [Line Items]              
License Costs       5,000      
Maximum [Member]              
Commitments and Contingencies [Line Items]              
License Costs       $ 20,000      
New Valeant Agreement [Member]              
Commitments and Contingencies [Line Items]              
Proceeds From Upfront Payment           $ 4,000,000  
New Valeant Agreement [Member] | Employee Stock Option [Member] | Two Executive And Seven Members [Member]              
Commitments and Contingencies [Line Items]              
Revenue Recognition, Milestone Method, Description     the Company is eligible to receive milestone payments totaling up to approximately $99.0 million, upon and subject to the achievement of certain specified developmental and commercial progress of the EGP-437 Product for the New Field. In addition, the Company is eligible under the New Valeant Agreement to receive royalties based on a specified percent of net sales of its EGP-437 Product for the New Field        
Licensor [Member]              
Commitments and Contingencies [Line Items]              
Area of Land | ft²           4,516  
Valeant Pharmaceuticals International Inc [Member] | Licensing Agreements [Member]              
Commitments and Contingencies [Line Items]              
Payments to Acquire Intangible Assets $ 1,000,000            
Proceeds from Sale of Intangible Assets $ 32,500,000